Key terms
About SLDB
Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest SLDB news
Apr 01
7:47am ET
Solid Biosciences receives Rae Pediatric Disease designation for SGT-003
Mar 28
9:52am ET
Palantir downgraded, CyberArk initiated: Wall Street’s top analyst calls
Mar 28
7:03am ET
Solid Biosciences initiated with an Outperform at William Blair
Mar 19
1:38am ET
Cautious Optimism Amidst Clinical Progress and Regulatory Hurdles for Solid Biosciences
Mar 18
5:51am ET
Solid Biosciences price target raised to $21 from $8 at Barclays
Mar 18
3:05am ET
Solid Biosciences (SLDB) Gets a Buy from Barclays
Mar 14
8:41pm ET
Solid Biosciences initiated with a Buy at Citi
Mar 14
8:30pm ET
Analysts Offer Insights on Healthcare Companies: Coherus Biosciences (CHRS) and Solid Biosciences (SLDB)
Mar 14
6:26am ET
Buy Rating Affirmed for Solid Biosciences on Promising Pipeline and Financial Stability
Mar 13
4:10pm ET
Piper upgrades Solid Biosciences to Overweight, still sees ‘significant upside’
Mar 13
4:07pm ET
Solid Biosciences upgraded to Overweight from Neutral at Piper Sandler
Mar 13
9:26am ET
Solid Biosciences files $300M mixed securities shelf
Mar 13
7:48am ET
Solid Biosciences expects cash to fund strategic priorities into 2026
Mar 13
7:48am ET
Solid Biosciences reports 2023 EPS ($4.83), consensus ($4.72)
Mar 11
6:17am ET
Solid Biosciences price target raised to $16 from $9 at H.C. Wainwright
Mar 11
12:48am ET
Leerink Partners Keeps Their Hold Rating on Solid Biosciences (SLDB)
Mar 07
7:12am ET
Solid Biosciences announces licensing agreement with Armatus Bio
Feb 05
4:06am ET
Hold Rating on Solid Biosciences Amid Gene Therapy Developments and Regulatory Milestones
Jan 30
4:12pm ET
Solid Biosciences files to sell 19.685M shares of common stock for holders
Jan 22
1:12pm ET
Piper Sandler Reaffirms Their Hold Rating on Solid Biosciences (SLDB)
Jan 11
6:14pm ET
Solid Biosciences’ treatment of DMD granted FDA orphan designation
Jan 08
9:57am ET
Solid Biosciences trading resumes
Jan 08
9:47am ET
Solid Biosciences trading halted, volatility trading pause
Jan 08
8:04am ET
Solid Biosciences to sell 16.97M shares at $5.53 in private placement
No recent press releases are available for SLDB
SLDB Financials
Key terms
Ad Feedback
SLDB Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
SLDB Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range